Company: ENTXW
Filing Date: 2025-03-17
Form Type: 8-K
Source: 0001178913-25-000857
Chunk: 1

Company: Entera Bio Ltd.
Filing Date: 2025-03-17
Form: 8-K
Item: Item 1.01
Chunk 1
---
 from the Program, while OPKO will
be solely responsible for ongoing development and commercialization funding of the Program.

Exclusivity. Pursuant to
the terms of the Collaboration Agreement, subject to certain limitations and exceptions, the Company and OPKO have agreed that, until the earlier of (x) the date of the Company’s determination to Opt-Out and (y) the expiration or termination of
the Collaboration Agreement, neither party shall conduct any internal program or program on behalf of a third party, or otherwise grant any right or license to a third party, that is directed to, or with respect to, the development or
commercialization of any GLP-1/glucagon dual agonist as an oral treatment form for treatment for patients with obesity, metabolic and/or fibrotic disorder.

Issuance of Ordinary Shares; Lockup and Standstill. In connection with the execution of the Collaboration Agreement, the Company issued and sold to OPKO, and OPKO purchased from
the Company, an aggregate of 3,685,226 ordinary shares, par value NIS 0.0000769, of the Company (the “ Purchased Shares”) for a purchase price of $8.0
million, representing a purchase price per share equal to approximately $2.17, which was the volume weighted average price per share for the 30 trading days immediately preceding the date of the Collaboration Agreement. OPKO has agreed to a
customary lockup with respect to the Purchased Shares, pursuant to which OPKO may not sell or otherwise transfer the Purchased Shares for a period of 12 months following the Effective Date, and OPKO has additionally agreed to a customary
“standstill” provision, pursuant to which, for a 24-month period following the Effective Date, OPKO may not acquire additional equity in the Company or otherwise take certain other actions, in each case without the Company’s consent.

The Company has agreed to use the proceeds from the sale of the Purchased Shares solely to fund its development cost obligations
under the Collaboration Agreement, and the Company has agreed to enter into an escrow arrangement, together with OPKO and an escrow agent, into which such proceeds will be deposited and subsequently disbursed to fund such development costs. If
the Collaboration Agreement expires or is terminated for any reason, any funds remaining in such escrow will be disbursed to the Company.

The offer, sale and issuance of the Purchased Shares were made in reliance on an exemption from registration provided by
Section 4(a